Literature DB >> 8516954

Structure and biology of amylin.

T J Rink1, K Beaumont, J Koda, A Young.   

Abstract

Amylin is a recently discovered 37 amino acid peptide secreted into the bloodstream, along with insulin, from pancreatic beta-cells. It is about 50% identical to calcitonin gene-related peptides (CGRP alpha and CGRP beta) and structurally related to the calcitonins. Amylin can elicit the vasodilator effects of CGRP and the hypocalcaemic actions of calcitonin, while these peptides can mimic newly discovered actions of amylin on carbohydrate metabolism. The different relative potencies of these peptides suggest that they act with different selectivities at a family of receptors. Amylin is deficient in insulin-dependent diabetes mellitus, while plasma levels are elevated in insulin-resistant conditions such as obesity and impaired glucose tolerance. In this Viewpoint article, Tim Rink and colleagues propose that amylin is an endocrine partner to insulin and glucagon; deficiency or excess of amylin may therefore contribute to important metabolic diseases.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8516954     DOI: 10.1016/0165-6147(93)90081-t

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  12 in total

1.  Amylin peptide levels are raised in infants of diabetic mothers.

Authors:  V Kairamkonda; A Deorukhkar; R Coombs; R Fraser; T Mayer
Journal:  Arch Dis Child       Date:  2005-09-20       Impact factor: 3.791

2.  Multiple receptors for calcitonin gene-related peptide and amylin on guinea-pig ileum and vas deferens.

Authors:  A E Tomlinson; D R Poyner
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

3.  A rat skeletal muscle cell line (L6) expresses specific adrenomedullin binding sites but activates adenylate cyclase via calcitonin gene-related peptide receptors.

Authors:  H A Coppock; A A Owji; S R Bloom; D M Smith
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

4.  Plasma amylin and insulin concentrations in normoglycemic and hyperglycemic cats.

Authors:  T A Lutz; J S Rand
Journal:  Can Vet J       Date:  1996-01       Impact factor: 1.008

Review 5.  A rational approach to drug therapy of type 2 diabetes mellitus.

Authors:  J M Chehade; A D Mooradian
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  Effects of amylin and other peptide hormones on Na+-K+ transport and contractility in rat skeletal muscle.

Authors:  T Clausen
Journal:  J Physiol       Date:  2000-08-15       Impact factor: 5.182

7.  Different pharmacological characteristics in L6 and C2C12 muscle cells and intact rat skeletal muscle for amylin, CGRP and calcitonin.

Authors:  R A Pittner; D Wolfe-Lopez; A A Young; K Beaumont
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 8.  Intermedin (adrenomedullin-2): a novel counter-regulatory peptide in the cardiovascular and renal systems.

Authors:  D Bell; B J McDermott
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

9.  Amylin tonally regulates arginine-stimulated insulin secretion in rats.

Authors:  W M Bennet; C S Beis; M A Ghatei; P G Byfield; S R Bloom
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

Review 10.  Amylin uncovered: a review on the polypeptide responsible for type II diabetes.

Authors:  Karen Pillay; Patrick Govender
Journal:  Biomed Res Int       Date:  2013-03-31       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.